دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Drug development for ulcerative proctitis: current concepts (31 March, 2021)
Bénédicte Caron, William J Sandborn, Stefan Schreiber, Remo Panaccione, Silvio Danese, Laurent Peyrin-Biroulet
doi : 10.1136/gutjnl-2021-324108
Gut 2021;70:1203-1209
Keeping the liver fit with TREM2 during hepatic carcinogenesis (4 November, 2020)
Francisco Javier Cubero
doi : 10.1136/gutjnl-2020-322638
Gut 2021;70:1210-1211
NAFLD-related mortality: simple hepatic steatosis is not as ‘benign’ as thought (19 October, 2020)
Herbert Tilg, Giovanni Targher
doi : 10.1136/gutjnl-2020-323188
Gut 2021;70:1212-1213
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (26 April, 2021)
Dipesh H Vasant, Peter A Paine, Christopher J Black, Lesley A Houghton, Hazel A Everitt, Maura Corsetti, Anurag Agrawal, Imran Aziz, Adam D Farmer, Maria P Eugenicos, Rona Moss-Morris, Yan Yiannakou, Alexander C Ford
doi : 10.1136/gutjnl-2021-324598
Gut 2021;70:1214-1240
Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS.
Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study (28 September, 2020)
Manuele Furnari, Leonardo Henry Eusebi, Edoardo Savarino, Carlo Petruzzellis, Gianluca Esposito, Marcello Maida, Luigi Ricciardiello, Silvia Pecere, Andrea Buda, Manuela De Bona, Cristiano Spada, Emilio Di Giulio, Guido Costamagna, Ivo Boskoski, Edoardo G Giannini
doi : 10.1136/gutjnl-2020-323116
Gut 2021;70:1241-1243
Original research: Endoscopic placement of covered versus uncovered self-expandable metal stents for palliation of malignant gastric outlet obstruction (22 November, 2020)
Kentaro Yamao, Masayuki Kitano, Yasutaka Chiba, Takeshi Ogura, Takaaki Eguchi, Ichiro Moriyama, Yukitaka Yamashita, Hironari Kato, Takahisa Kayahara, Noriyuki Hoki, Yoshinobu Okabe, Hideyuki Shiomi, Yoshitaka Nakai, Yoshinori Kushiyama, Yoshifumi Fujimoto, Shiro Hayashi, Shigeki Bamba, Yasushi Kudo, Nobuaki Azemoto, Toshiharu Ueki, Norimitsu Uza, Masanori Asada, Kazuya Matsumoto, Hiroko Nebiki, Hiroshi Takihara, Chisio Noguchi, Hideki Kamada, Kojiro Nakase, Daisuke Goto, Tsuyoshi Sanuki, Tetsuya Koga, Shinichi Hashimoto, Hidefumi Nishikiori, Masahiro Serikawa, Keiji Hanada, Ken Hirao, Masaya Ohana, Imakiire Kazuyuki, Takao Kato, Motoyuki Yoshida, Hirofumi Kawamoto
doi : 10.1136/gutjnl-2020-320775
Gut 2021;70:1244-1252
Stenting is an established endoscopic therapy for malignant gastric outlet obstruction (mGOO). The choice of stent (covered vs uncovered) has been examined in prior randomised studies without clear results.
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19 (31 March, 2021)
Zhigang Ren, Haiyu Wang, Guangying Cui, Haifeng Lu, Ling Wang, Hong Luo, Xinhua Chen, Hongyan Ren, Ranran Sun, Wenli Liu, Xiaorui Liu, Chao Liu, Ang Li, Xuemei Wang, Benchen Rao, Chengyu Yuan, Hua Zhang, Jiarui Sun, Xiaolong Chen, Bingjie Li, Chuansong Hu, Zhongwen Wu, Zujiang Yu, Quancheng Kan, Lanjuan Li
doi : 10.1136/gutjnl-2020-323826
Gut 2021;70:1253-1265
To characterise the oral microbiome, gut microbiome and serum lipid profiles in patients with active COVID-19 and recovered patients; evaluate the potential of the microbiome as a non-invasive biomarker for COVID-19; and explore correlations between the microbiome and lipid profile.
Original research: Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life (12 October, 2020)
Shannon Linda Kanis, Sanne Modderman, Johanna C Escher, Nicole Erler, Ruud Beukers, Nanne de Boer, Alexander Bodelier, Annekatrien C T.M Depla, Gerard Dijkstra, Anne-Baue Ruth Margaretha van Dijk, Lennard Gilissen, Frank Hoentjen, Jeroen M Jansen, Johan Kuyvenhoven, Nofel Mahmmod, Rosalie C Mallant-Hent, Andrea E van der Meulen-de Jong, Anahita Noruzi, Bas Oldenburg, Liekele E Oostenbrug, Pieter C.J. Ter Borg, Marieke Pierik, Mariëlle Romberg- Camps, Willem Thijs, Rachel West, Alison de Lima, C Janneke van der Woude
doi : 10.1136/gutjnl-2019-319129
Gut 2021;70:1266-1274
The aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.
Original research: Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS (6 October, 2020)
Eluisa Perna, Javier Aguilera-Lizarraga, Morgane V Florens, Piyush Jain, Stavroula A Theofanous, Nikita Hanning, Joris G De Man, Maya Berg, Benedicte De Winter, Yeranddy A Alpizar, Karel Talavera, Pieter Vanden Berghe, Mira Wouters, Guy Boeckxstaens
doi : 10.1136/gutjnl-2020-321530
Gut 2021;70:1275-1286
Resolvins (RvD1, RvD2 and RvE1) are endogenous anti-inflammatory lipid mediators that display potent analgesic properties in somatic pain by modulating transient receptor potential vanilloid 1 (TRPV1) activation. To what extent these molecules could also have a beneficial effect on TRPV1 sensitisation and visceral hypersensitivity (VHS), mechanisms involved in IBS, remains unknown.
Original research: Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiomeEditor's Choice (2 April, 2021)
Laura A Bolte, Arnau Vich Vila, Floris Imhann, Valerie Collij, Ranko Gacesa, Vera Peters, Cisca Wijmenga, Alexander Kurilshikov, Marjo J E Campmans-Kuijpers, Jingyuan Fu, Gerard Dijkstra, Alexandra Zhernakova, Rinse K Weersma
doi : 10.1136/gutjnl-2020-322670
Gut 2021;70:1287-1298
The microbiome directly affects the balance of pro-inflammatory and anti-inflammatory responses in the gut. As microbes thrive on dietary substrates, the question arises whether we can nourish an anti-inflammatory gut ecosystem. We aim to unravel interactions between diet, gut microbiota and their functional ability to induce intestinal inflammation.
Original research: Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury (1 October, 2020)
Laura Wrzosek, Dragos Ciocan, Cindy Hugot, Madeleine Spatz, Margot Dupeux, Camille Houron, Vanessa Lievin-Le Moal, Virginie Puchois, Gladys Ferrere, Nicolas Trainel, Françoise Mercier-Nomé, Sylvere Durand, Guido Kroemer, Cosmin Sebastian Voican, Patrick Emond, Marjolène Straube, Harry Sokol, Gabriel Perlemuter, Anne-Marie Cassard
doi : 10.1136/gutjnl-2020-321565
Gut 2021;70:1299-1308
Chronic alcohol consumption is an important cause of liver-related deaths. Specific intestinal microbiota profiles are associated with susceptibility or resistance to alcoholic liver disease in both mice and humans. We aimed to identify the mechanisms by which targeting intestinal microbiota can improve alcohol-induced liver lesions.
Original research: Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors (6 October, 2020)
Elisabeth Waldmann, Daniela Penz, Hana ?inkovec, Georg Heinze, Christoph Rinner, Lena Jiricka, Barbara Majcher, Anna Hinterberger, Michael Trauner, Monika Ferlitsch
doi : 10.1136/gutjnl-2019-319427
Gut 2021;70:1309-1317
Postscreening colorectal cancer (PSCRC) after screening colonoscopy is associated with endoscopists’ performance and characteristics of resected lesions. Prior studies have shown that adenoma detection rate (ADR) is a decisive factor for PSCRC, but correlations with other parameters need further analysis and ADR may change over time.
Original research: Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme (28 September, 2020)
Szu-Min Peng, Wen-Feng Hsu, Ying-Wei Wang, Li-Ju Lin, Amy Ming-Fang Yen, Li-Sheng Chen, Yi-Chia Lee, Ming-Shiang Wu, Tony Hsiu-Hsi Chen, Han-Mo Chiu
doi : 10.1136/gutjnl-2020-320761
Gut 2021;70:1318-1324
Subjects with a positive faecal immunochemical test (FIT) have a much higher likelihood of advanced neoplasms than the general population. Whether FIT-positive subjects with negative colonoscopy should receive subsequent FIT screening remain unclear.
Original research: Genetic architectures of proximal and distal colorectal cancer are partly distinct (25 February, 2021)
Jeroen R Huyghe, Tabitha A Harrison, Stephanie A Bien, Heather Hampel, Jane C Figueiredo, Stephanie L Schmit, David V Conti, Sai Chen, Conghui Qu, Yi Lin, Richard Barfield, John A Baron, Amanda J Cross, Brenda Diergaarde, David Duggan, Sophia Harlid, Liher Imaz, Hyun Min Kang, David M Levine, Vittorio Perduca, Aurora Perez-Cornago, Lori C Sakoda, Fredrick R Schumacher, Martha L Slattery, Amanda E Toland, Fr?nzel J B van Duijnhoven, Bethany Van Guelpen, Antonio Agudo, Demetrius Albanes, M Henar Alonso, Kristin Anderson, Coral Arnau-Collell, Volker Arndt, Barbara L Banbury, Michael C Bassik, Sonja I Berndt, Stéphane Bézieau, D Timothy Bishop, Juergen Boehm, Heiner Boeing, Marie-Christine Boutron-Ruault, Hermann Brenner, Stefanie Brezina, Stephan Buch, Daniel D Buchanan, Andrea Burnett-Hartman, Bette J Caan, Peter T Campbell, Prudence R Carr, Antoni Castells, Sergi Castellv?-Bel, Andrew T Chan, Jenny Chang-Claude, Stephen J Chanock, Keith R Curtis, Albert de la Chapelle, Douglas F Easton, Dallas R English, Edith J M Feskens, Manish Gala, Steven J Gallinger, W James Gauderman, Graham G Giles, Phyllis J Goodman, William M Grady, John S Grove, Andrea Gsur, Marc J Gunter, Robert W Haile, Jochen Hampe, Michael Hoffmeister, John L Hopper, Wan-Ling Hsu, Wen-Yi Huang, Thomas J Hudson, Mazda Jenab, Mark A Jenkins, Amit D Joshi, Temitope O Keku, Charles Kooperberg, Tilman Kühn, Sébastien Küry, Loic Le Marchand, Flavio Lejbkowicz, Christopher I Li, Li Li, Wolfgang Lieb, Annika Lindblom, Noralane M Lindor, Satu M?nnist?, Sanford D Markowitz, Roger L Milne, Lorena Moreno, Neil Murphy, Rami Nassir, Kenneth Offit, Shuji Ogino, Salvatore Panico, Patrick S Parfrey, Rachel Pearlman, Paul D P Pharoah, Amanda I Phipps, Elizabeth A Platz, John D Potter, Ross L Prentice, Lihong Qi, Leon Raskin, Gad Rennert, Hedy S Rennert, Elio Riboli, Clemens Schafmayer, Robert E Schoen, Daniela Seminara, Mingyang Song, Yu-Ru Su, Catherine M Tangen, Stephen N Thibodeau, Duncan C Thomas, Antonia Trichopoulou, Cornelia M Ulrich, Kala Visvanathan, Pavel Vodicka, Ludmila Vodickova, Veronika Vymetalkova, Korbinian Weigl, Stephanie J Weinstein, Emily White, Alicja Wolk, Michael O Woods, Anna H Wu, Goncalo R Abecasis, Deborah A Nickerson, Peter C Scacheri, Anshul Kundaje, Graham Casey, Stephen B Gruber, Li Hsu, Victor Moreno, Richard B Hayes, Polly A Newcomb, Ulrike Peters
doi : 10.1136/gutjnl-2020-321534
Gut 2021;70:1325-1334
An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics and environmental risk factors among tumors arising in different locations of the colorectum suggest partly distinct mechanisms of carcinogenesis. The extent to which the contribution of inherited genetic risk factors for CRC differs by anatomical subsite of the primary tumor has not been examined.
Original research: Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis (7 October, 2020)
Neil B Marya, Patrick D Powers, Suresh T Chari, Ferga C Gleeson, Cadman L Leggett, Barham K Abu Dayyeh, Vinay Chandrasekhara, Prasad G Iyer, Shounak Majumder, Randall K Pearson, Bret T Petersen, Elizabeth Rajan, Tarek Sawas, Andrew C Storm, Santhi S Vege, Shigao Chen, Zaiyang Long, David M Hough, Kristin Mara, Michael J Levy
doi : 10.1136/gutjnl-2020-322821
Gut 2021;70:1335-1344
The diagnosis of autoimmune pancreatitis (AIP) is challenging. Sonographic and cross-sectional imaging findings of AIP closely mimic pancreatic ductal adenocarcinoma (PDAC) and techniques for tissue sampling of AIP are suboptimal. These limitations often result in delayed or failed diagnosis, which negatively impact patient management and outcomes. This study aimed to create an endoscopic ultrasound (EUS)-based convolutional neural network (CNN) model trained to differentiate AIP from PDAC, chronic pancreatitis (CP) and normal pancreas (NP), with sufficient performance to analyse EUS video in real time.
Original research: TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms (9 September, 2020)
Aitor Esparza-Baquer, Ibone Labiano, Omar Sharif, Alo?a Agirre-Lizaso, Fiona Oakley, Pedro M Rodrigues, Ekaterina Zhuravleva, Colm J O'Rourke, Elizabeth Hijona, Raul Jimenez-Agüero, Ioana Ria?o, Ana Landa, Adelaida La Casta, Marco Y W Zaki, Patricia Munoz-Garrido, Mikel Azkargorta, Felix Elortza, Andrea Vogel, Gernot Schabbauer, Patricia Aspichueta, Jesper B Andersen, Sylvia Knapp, Derek A Mann, Luis Bujanda, Jesus Maria Banales, Maria Jesus Perugorria
doi : 10.1136/gutjnl-2019-319227
Gut 2021;70:1345-1361
Hepatocellular carcinoma (HCC) is a prevalent and aggressive cancer usually arising on a background of chronic liver injury involving inflammatory and hepatic regenerative processes. The triggering receptor expressed on myeloid cells 2 (TREM-2) is predominantly expressed in hepatic non-parenchymal cells and inhibits Toll-like receptor signalling, protecting the liver from various hepatotoxic injuries, yet its role in liver cancer is poorly defined. Here, we investigated the impact of TREM-2 on liver regeneration and hepatocarcinogenesis.
Original research: Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma (26 October, 2020)
Juan Bayo, Esteban J Fiore, Luciana Mar?a Dominguez, Mar?a Jose Cantero, Matias S Ciarlantini, Mariana Malvicini, Catalina Atorrasagasti, Mariana Gabriela Garcia, Mario Rossi, Claudio Cavasotto, Elisabeth Martinez, Julieta Comin, Guillermo D Mazzolini
doi : 10.1136/gutjnl-2020-321454
Gut 2021;70:1362-1374
The RHO family of GTPases, particularly RAC1, has been linked with hepatocarcinogenesis, suggesting that their inhibition might be a rational therapeutic approach. We aimed to identify and target deregulated RHO family members in human hepatocellular carcinoma (HCC).
Original research: Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort (9 October, 2020)
Tracey G Simon, Bjorn Roelstraete, Hamed Khalili, Hannes Hagstr?m, Jonas F Ludvigsson
doi : 10.1136/gutjnl-2020-322786
Gut 2021;70:1375-1382
Population-based data are lacking regarding the risk of overall and cause-specific mortality across the complete histological spectrum of non-alcoholic fatty liver disease (NAFLD).
Niche-specific functional heterogeneity of intestinal resident macrophages (31 December, 2020)
Maria Francesca Viola, Guy Boeckxstaens
doi : 10.1136/gutjnl-2020-323121
Gut 2021;70:1383-1395
Intestinal resident macrophages are at the front line of host defence at the mucosal barrier within the gastrointestinal tract and have long been known to play a crucial role in the response to food antigens and bacteria that are able to penetrate the mucosal barrier. However, recent advances in single-cell RNA sequencing technology have revealed that resident macrophages throughout the gut are functionally specialised to carry out specific roles in the niche they occupy, leading to an unprecedented understanding of the heterogeneity and potential biological functions of these cells. This review aims to integrate these novel findings with long-standing knowledge, to provide an updated overview on our understanding of macrophage function in the gastrointestinal tract and to speculate on the role of specialised subsets in the context of homoeostasis and disease.
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future (11 January, 2021)
Geert R D'Haens, Sander van Deventer
doi : 10.1136/gutjnl-2019-320022
Gut 2021;70:1396-1405
Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25 years now. The first clinical observations in patients with refractory Crohn’s disease rapidly responding to infliximab prompted accelerated clinical development and approval for this indication. However, many questions remained unanswered when this treatment came to market related to maintenance schedules, pharmacokinetics, toxicity and positioning. Many of these open questions were addressed by investigators and sponsors during more than two decades of clinical use. The authors were among the first to use infliximab in Crohn’s disease and felt that now is a good time to look back and draw lessons from the remarkable anti-TNF story. Even today, new insights continue to appear. But more importantly, what was learnt in the past 25 years has created a platform for future development of even stronger and safer therapies. We should not forget to learn from the past.
GI highlights from the literature (7 June, 2021)
Philip J Smith
doi : 10.1136/gutjnl-2021-325156
Gut 2021;70:1406-1407
Letter: COVID-19 in patients with cirrhosis: understanding adverse impact (21 August, 2020)
Sanchit Sharma, Anshuman Elhence, Manas Vaishnav, Ramesh Kumar, Shalimar
doi : 10.1136/gutjnl-2020-322561
Gut 2021;70:1409
Letter: Time series analysis of microbiome and metabolome at multiple body sites in steady long-term isolation confinement (10 September, 2020)
Qiang Feng, Xiang Lan, Xiaoli Ji, Meihui Li, Shili Liu, Jianghui Xiong, Yanbo Yu, Zhipeng Liu, Zi Xu, Li He, Ying Chen, Haisheng Dong, Pu Chen, Bin Chen, Kunlun He, Yinghui Li
doi : 10.1136/gutjnl-2020-320666
Gut 2021;70:1409-1412
Letter: Modulating immunosuppression in liver transplant patients with COVID-19 (18 August, 2020)
Manuel Rodriguez-Peralvarez, Magdalena Salcedo, Jordi Colmenero, Jose Antonio Pons
doi : 10.1136/gutjnl-2020-322620
Gut 2021;70:1412-1414
Letter: COVID-19 and its impact on endoscopy services: what is the threshold for missed malignant diagnosis? (26 August, 2020)
Tony He, Michael B MacIsaac, Simon J Hume, Alexander J Thompson, Julien D Schulberg
doi : 10.1136/gutjnl-2020-322769
Gut 2021;70:1414-1415
Rare APC promoter 1B variants in gastric cancer kindreds unselected for fundic gland polyposis (7 September, 2020)
Katherine Dixon, Janine Senz, Pardeep Kaurah, David G Huntsman, Kasmintan A Schrader
doi : 10.1136/gutjnl-2020-321990
Gut 2021;70:1415-1416
Letter: Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn’s disease (14 September, 2020)
Bram Verstockt, Liesbeth Boets, Jo?o Sabino, Séverine Vermeire, Marc Ferrante
doi : 10.1136/gutjnl-2020-322646
Gut 2021;70:1416-1418
Don’t judge a book by its cover: except during optical evaluation (27 March, 2020)
Neal Shahidi, W Arnout van Hattem, Sergei Vosko, Michael J Bourke
doi : 10.1136/gutjnl-2020-320829
Gut 2021;70:1252-1286
